Gilead Sciences Inc (GILD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $208.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
Gilead Sciences Inc (GILD) Valuation Multiples
Gilead Sciences (GILD) trades at 6.7x sales and 16.0x book value. Its P/S of 6.7x is above its 5-year median of 3.8x. Its forward P/E is 16.8x.
Current Multiples
Its enterprise value is 176.3x its EBITDA. Its free cash flow yield is 6.6%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 16.8x |
| Price to sales | 6.7x |
| Price to book | 16.0x |
| EV/EBITDA | 176.3x |
| Price to FCF | 15.1x |
| EV/FCF | 16.5x |
| PEG | N/A |
| FCF yield | 6.6% |
Historical Medians
Against its 10-year medians, its P/S is 81.1% above 3.7x and its P/B is 255.6% above 4.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | N/A | 13.6x | 10.0x |
| P/S | 6.7x | 3.8x | 3.7x |
| P/B | 16.0x | 5.1x | 4.5x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 6.2x in 2016 to 20.0x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $122.74 | 15.1x | 5.2x | 6.8x |
| 2024 | $92.37 | 20.0x | 4.0x | 6.0x |
| 2023 | $81.01 | 12.1x | 3.7x | 4.5x |
| 2022 | $85.85 | 11.8x | 4.0x | 5.1x |
| 2021 | $72.61 | 10.0x | 3.3x | 4.3x |
| 2020 | $58.26 | 8.2x | 3.0x | 4.0x |
| 2019 | $64.98 | 9.8x | 3.7x | 3.7x |
| 2018 | $62.55 | 9.4x | 3.7x | 3.8x |
| 2017 | $71.64 | 8.1x | 3.6x | 4.6x |
| 2016 | $71.61 | 6.2x | 3.2x | 4.9x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GILD
What is GILD's forward P/E ratio?
Gilead Sciences has a forward P/E ratio of 16.8x.
Is GILD stock overvalued?
GNG's valuation label for GILD is Overvalued.
What is GILD's price to sales ratio?
Gilead Sciences has a price to sales ratio of 6.7x.
What is Gilead Sciences's average P/E ratio over 5 years?
Gilead Sciences's median P/E over the last 5 years is 13.6x, from 55 month-end values through Oct 2026.
GILD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts